These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16403905)

  • 1. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
    Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
    Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
    Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
    Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
    Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
    Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
    Faderl S; Gandhi V; O'Brien S; Bonate P; Cortes J; Estey E; Beran M; Wierda W; Garcia-Manero G; Ferrajoli A; Estrov Z; Giles FJ; Du M; Kwari M; Keating M; Plunkett W; Kantarjian H
    Blood; 2005 Feb; 105(3):940-7. PubMed ID: 15486072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
    Martínez-Cuadrón D; Montesinos P; Oriol A; Salamero O; Vidriales B; Bergua J; Herrera P; Vives S; Sanz J; Carpio C; Rodríguez-Veiga R; Moscardó F; Sanz MA
    Ann Hematol; 2014 Jan; 93(1):43-6. PubMed ID: 24081577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
    Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
    Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
    Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
    Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
    J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
    Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
    Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
    Tran H; Yang D
    Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.